Please assess the completion status of the following clinical trial:

Trial Title: Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older;~* Pathological diagnosis of patients with stage II, III A primary NSCLC;~* R0 resection has been accepted;~* Received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery;~* Informed consent has been signed.~Exclusion Criteria:~* Incorporation of other malignant tumors (such as leukemia, liver cancer, etc.);~* Patients with unclear pathological types;~* Patients with unclear pathological staging;~* Preserved Shenlingcao Oral Liquid before R0 resection surgery;~* Received immunotherapy or targeted therapy before R0 resection surgery;~* Radiotherapy and chemotherapy before R0 resection surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
- Control group (Type: NO_INTERVENTION): Patients receive conventional adjuvant chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).